8/25/2009
National Cancer Institute Phase II Bridge Award
by Rebecca Norman, Graduate Assistant, UALR Lead Center
Small businesses that have received a Small Business Innovation Research (SBIR) Phase II award through the National Institute of Health (NIH) for oncology-related projects and are interested in commercialization funding opportunities may benefit from investigating the National Cancer Institute's (NCI) SBIR Phase II Bridge Award announcement. This NCI announcement is for informational purposes only and is not a call for Phase II Bridge Award proposals. The previously-offered NCI SBIR Phase II Bridge Award is intended to assist select SBIR Phase II awardees with the long-term costs that are associated with commercializing their new technology.
The NCI is specifically interested in SBIR projects that are intended to benefit cancer patients by accelerating the development of new cancer therapies and imaging devices or technologies toward commercialization. Only applications that propose projects in these areas of oncology will be considered responsive to the SBIR Phase II Bridge Award announcement. Letters of intent are due by January 27, 2009 and applications are due by February 27, 2009. The SBIR Phase II Bridge award announcement does not commit the government to the development of a SBIR Phase II Bridge Award mechanism for making such awards to contract awardees.
The specific requirements for the SBIR Phase II Bridge Award can be reviewed in the full Request for Application announcement (http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-08-021.html).
Selection decisions for Phase II Bridge Awards will be based both on scientific and technical merit as well as commercialization potential.
For more information on SBIR programs, contact Rebecca Norman at rxnorman@ualr.edu, 501.569.7705 or (800) 862-2040 (AR only).
